Jazz Pharma Ireland Ltd v. Tris Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Jazz Pharmaceuticals Ireland Limited (Ireland)
  • Defendant: Tris Pharma, Inc. (New Jersey)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 2:26-cv-01739, D.N.J., 02/20/2026
• Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the Defendant is a New Jersey corporation with its principal place of business in the district, has conducted business in the district, and the district is a likely destination for the accused product. The complaint also notes that Defendant has previously availed itself of the jurisdiction of this Court in other matters.
• Core Dispute: Plaintiff alleges that Defendant's submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Plaintiff's Xyrem® (sodium oxybate) drug product constitutes an act of infringement of seven patents related to methods of administering gamma hydroxybutyrate (GHB).
• Technical Context: The technology concerns pharmaceutical methods for safely administering GHB, a treatment for narcolepsy, by adjusting dosage to account for drug-drug interactions with a class of compounds known as monocarboxylate transporter (MCT) inhibitors, such as valproate.
• Key Procedural History: This lawsuit was initiated under the Hatch-Waxman Act following Defendant's submission of an NDA with a Paragraph IV Certification, which asserts that Plaintiff's patents-in-suit are invalid, unenforceable, and/or will not be infringed by Defendant's proposed generic product. The complaint notes the existence of other consolidated litigation involving the same plaintiff and certain of the same patents.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,772,306 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 8772306, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued July 8, 2014 (the '306 Patent).

The Invention Explained

• Problem Addressed: The patent describes the discovery that the concomitant administration of a monocarboxylate transporter (MCT) inhibitor, such as valproate, can increase the effect of gamma-hydroxybutyrate (GHB) in the body, which may lead to an unsafe condition for a patient '306 Patent, abstract
• The Patented Solution: The invention provides a method for safely administering GHB to a patient by adjusting the dosage to account for the effects of a co-administered MCT inhibitor '306 Patent, col. 1:19-24 Specifically, when GHB is administered with valproate, the patented method involves reducing the dosage of GHB to diminish the additive effects and improve safety '306 Patent, col. 1:28-49
• Technical Importance: The claimed methods allow for the safe co-administration of GHB, a primary treatment for narcolepsy, with other commonly prescribed drugs that could otherwise cause dangerous drug-drug interactions '306 Patent, background section

Key Claims at a Glance

• The complaint asserts "one or more claims" of the '306 Patent Compl. ¶29 Independent claim 1 is representative of the invention.
• The essential elements of independent claim 1 include:
  • A method for treating a patient suffering from conditions including excessive daytime sleepiness or cataplexy in narcolepsy with GHB or a salt thereof.
  • Orally administering an adjusted dosage amount of the salt of GHB.
  • The adjustment occurs when the patient is receiving a concomitant administration of valproate.
  • The adjusted amount is reduced at least about 1% to 50% of the normal dose.
  • The daily administration of the GHB salt is between 1 gram and 10 grams.
• The complaint alleges infringement of "one or more" claims, which implicitly reserves the right to assert additional dependent and independent claims Compl. ¶29

U.S. Patent No. 9,050,302 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 9050302, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued June 9, 2015 (the '302 Patent).

The Invention Explained

• Problem Addressed: As with the related '306 Patent, the '302 Patent addresses the safety and efficacy concerns arising from the co-administration of GHB with MCT inhibitors like valproate, which can dangerously increase the effect of GHB '302 Patent, abstract
• The Patented Solution: The patent claims methods for reducing the adverse effects of combining GHB and divalproex sodium (a form of valproate) by administering a reduced daily dosage of GHB compared to the dosage that would be administered in the absence of divalproex sodium '302 Patent, col. 25:6-18 The method specifies a percentage reduction and a baseline dosage range '302 Patent, claim 1
• Technical Importance: This provides physicians with a specific, claimed dosing protocol to mitigate the risks of a known drug-drug interaction, enhancing patient safety for those requiring both medications '302 Patent, background section

Key Claims at a Glance

• The complaint asserts "one or more claims" of the '302 Patent Compl. ¶38 Independent claim 1 is representative.
• The essential elements of independent claim 1 include:
  • A method for reducing adverse effects from a combination of GHB and divalproex sodium.
  • For a patient suffering from cataplexy in narcolepsy or excessive daytime sleepiness in narcolepsy.
  • Administering a reduced daily dosage of GHB that is between about 5% to 35% lower than the dosage administered in the absence of divalproex sodium.
  • Wherein the daily dosage of GHB in the absence of concomitant administration of divalproex sodium is between 4.5 g to 9 g.
• The complaint alleges infringement of "one or more" claims, implicitly reserving the right to assert additional dependent and independent claims Compl. ¶38

U.S. Patent No. 9,486,426 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 9486426, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued November 8, 2016 (the '426 Patent).
• Technology Synopsis: The '426 Patent, part of the same family as the '306 and '302 patents, addresses the safety issues that arise when co-administering GHB with MCT inhibitors like valproate '426 Patent, abstract It claims methods of adjusting GHB dosage to compensate for these drug-drug interactions '426 Patent, col. 1:29-50
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶47
• Accused Features: The accused infringing act is Defendant's submission of NDA No. 220138 for its proposed generic oxybate product, which is alleged to seek approval for uses covered by the patent's claims Compl. ¶47

U.S. Patent No. 10,213,400 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 10213400, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued February 26, 2019 (the '400 Patent).
• Technology Synopsis: The '400 Patent continues the same subject matter, claiming methods for safely administering GHB by adjusting its dosage when a patient is also receiving an MCT inhibitor such as valproate or diclofenac '400 Patent, abstract The methods are intended to prevent unsafe conditions caused by the drug-drug interaction '400 Patent, Summary of the Invention
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶56
• Accused Features: The accused infringing act is Defendant's submission of an NDA for its proposed generic oxybate product Compl. ¶56

U.S. Patent No. 10,864,181 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 10864181, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued December 15, 2020 (the '181 Patent).
• Technology Synopsis: The '181 Patent is also directed to methods of safely administering GHB in the presence of an MCT inhibitor. The claims cover adjusting the dosage of GHB to either reduce additive effects (when co-administered with valproate) or compensate for reduced efficacy (when co-administered with diclofenac) '181 Patent, abstract '181 Patent, col. 1:15-24
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶65
• Accused Features: Infringement is based on Defendant's submission of an NDA for a generic oxybate product intended for uses claimed in the patent Compl. ¶65

U.S. Patent No. 11,253,494 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 11253494, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued February 22, 2022 (the '494 Patent).
• Technology Synopsis: The '494 Patent continues to claim methods for managing the drug-drug interaction between GHB and MCT inhibitors. The invention involves adjusting the GHB dosage to ensure patient safety and efficacy when drugs like valproate or diclofenac are co-prescribed '494 Patent, abstract '494 Patent, col. 1:26-34
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶74
• Accused Features: The alleged infringement stems from Defendant's filing of an NDA for a generic version of Xyrem® Compl. ¶74

U.S. Patent No. 11,986,446 - Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

• Patent Identification: U.S. Patent No. 11986446, entitled "Method of administration of gamma hydroxybutyrate with monocarboxylate transporters," issued May 21, 2024 (the '446 Patent).
• Technology Synopsis: The '446 Patent is the most recent patent in the asserted family and covers similar subject matter: methods for safely administering GHB by adjusting its dosage in view of concomitant administration of an MCT inhibitor '446 Patent, abstract The claims are designed to mitigate potentially unsafe conditions arising from this drug combination '446 Patent, Summary of the Invention
• Asserted Claims: The complaint alleges infringement of "one or more claims" Compl. ¶83
• Accused Features: The basis for infringement is Defendant's submission of its NDA seeking approval to market a generic oxybate product Compl. ¶83

III. The Accused Instrumentality

Product Identification

• The accused instrumentality is identified as "Tris's Proposed Product," an oxybate drug product for which Defendant Tris Pharma, Inc. submitted New Drug Application No. 220138 to the FDA Compl. ¶1 Compl. ¶24

Functionality and Market Context

• The complaint alleges this product is a version of Jazz Pharmaceuticals' Xyrem® drug product Compl. ¶1 Xyrem® is a brand name for sodium oxybate, used to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy Compl. ¶11 Compl. ¶13 The complaint alleges that upon FDA approval, Tris will manufacture, use, sell, or import this product in the United States, placing it in direct competition with Xyrem® Compl. ¶25 The act of infringement alleged is the submission of the NDA itself under 35 U.S.C. § 271(e)(2)(A), which allows for litigation prior to the commercial launch of a generic drug Compl. ¶29
  No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed infringement theory or claim chart mapping specific features of the accused product to the elements of the asserted patent claims. The infringement allegation is a statutory one arising under the Hatch-Waxman Act, where the submission of an NDA for a generic version of a branded drug is itself an act of infringement if the commercialization of that drug would infringe a valid patent Compl. ¶29 Compl. ¶38 The narrative theory of infringement is that by seeking approval to market a generic version of Xyrem®, Tris is also seeking approval for the methods of use covered by the patents-in-suit Compl. ¶1 Compl. ¶15 The complaint alleges that the labeling for Xyrem® instructs and encourages administration according to the claimed methods, including dose modifications for concomitant use with other drugs Compl. ¶14 Compl. ¶15 The implication is that Tris's proposed generic product will carry a substantially similar label, thereby inducing physicians and patients to perform the patented methods.

• Identified Points of Contention:
  • Label-Based Inducement: A primary point of contention will be whether the proposed label for Tris's Proposed Product instructs, encourages, or requires users to perform all steps of the asserted method claims. The infringement analysis may turn on the specific language used in Tris's proposed label relative to the claims.
  • Claim Scope: The parties may dispute whether the real-world administration of a generic oxybate product would meet all limitations of the asserted claims. For instance, questions may arise as to what actions constitute an "adjusted dosage amount" or "concomitant administration" as those terms are used in the claims.

V. Key Claim Terms for Construction

• The Term: "concomitant administration"

• Context and Importance: This term is central to all asserted patents, as the claimed dosage adjustments are triggered by the co-administration of GHB with an MCT inhibitor like valproate. The temporal scope of "concomitant" will be critical; a narrow construction (e.g., simultaneous intake) might support a finding of non-infringement, while a broader construction (e.g., taken during the same overall treatment period) may support the plaintiff's infringement theory.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification of the related '181 Patent states that "'Concomitant' and 'concomitantly' as used herein refer to the administration of at least two drugs to a patient either subsequently, simultaneously, or consequently within a time period during which the effects of the first administered drug are still operative," which could be "within two weeks, preferably within one week or even three days" '181 Patent, col. 20:55-62 This language may support an interpretation that covers typical overlapping prescription periods.
  • Evidence for a Narrower Interpretation: A defendant may argue that the clinical studies described in the patent, which form the basis of the invention, involved administration over a more discrete and proximate timeframe, suggesting the term should be limited to that context '400 Patent, col. 21:1-col. 22:50

• The Term: "adjusted dosage amount" / "reduced daily dosage amount"

• Context and Importance: These terms define the core inventive step of the patents. The dispute may focus on whether the claims require proof that a physician made a conscious decision to reduce the GHB dose specifically because of the co-administration of valproate, or whether it is sufficient that a patient on valproate is simply prescribed a GHB dose that falls within the claimed reduced range.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The claims quantify the reduction with specific percentage ranges (e.g., "reduced...of between about 5% to about 35%") '302 Patent, claim 1 A plaintiff may argue that any prescription meeting these numerical limitations for a patient on valproate literally infringes, regardless of the physician's subjective reasoning.
  • Evidence for a Narrower Interpretation: Language in the specification such as adjusting the dose "to compensate for the effect caused by valproate" '181 Patent, col. 3:49-51 may suggest a purpose-based limitation. A defendant could argue this requires evidence of a specific intent to adjust the dose for the stated reason, which may be difficult to establish from a product label alone.

VI. Other Allegations

• Indirect Infringement: The complaint alleges both induced and contributory infringement for all seven patents-in-suit Compl. ¶¶32-33 Compl. ¶¶41-42 Compl. ¶¶50-51 Compl. ¶¶59-60 Compl. ¶¶68-69 Compl. ¶¶77-78 Compl. ¶¶86-87 The basis for inducement is the allegation that, upon FDA approval, Defendant will "intentionally encourage acts of direct infringement" with knowledge of the patents, presumably through its product labeling and marketing materials Compl. ¶32 The basis for contributory infringement is the allegation that the proposed product is "especially adapted for a use that infringes" and has "no substantial non-infringing use" Compl. ¶33
• Willful Infringement: The complaint does not explicitly allege willful infringement or seek enhanced damages. However, it does allege that the case is "exceptional" and seeks an award of attorneys' fees under 35 U.S.C. § 285 Compl. ¶36 The factual basis for this appears to be Defendant's pre-suit knowledge of the patents, as evidenced by its Paragraph IV Certification letter Compl. ¶27

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of induced infringement: does the proposed FDA label for Defendant's generic oxybate product contain instructions or recommendations that will inevitably lead at least some physicians or patients to practice the patented methods of adjusting GHB dosage when co-administered with MCT inhibitors like valproate?
• A key legal question will be one of definitional scope: can the term "concomitant administration," as used in the patents, be construed to cover the common clinical scenario where two drugs are prescribed for overlapping periods, or will it be limited to a narrower timeframe that is less likely to be directly instructed on a product label?
• A foundational question for the litigation, stemming from the Defendant's Paragraph IV challenge, will be the validity of the patents-in-suit. The case will likely require the court to determine whether the claimed dosage adjustments were non-obvious and novel contributions to the art at the time of the invention.